Search Results
Sep 09, 2026, 09:00 ET Rakuten Medical Appoints Christophe Weber as Vice Chairman and Ken Takeshita, M.D., as Director to Accelerate U.S. Growth and Oncology Innovation
he spent more than 20 years at GlaxoSmithKline (GSK), where he held senior leadership positions across Europe, the United States, and Asia, including President and CEO of GSK France, Regional Head of Asia Pacific, and President and General Manager of GSK Vaccines. Most recently, he joined the Board of
More news about: Rakuten Medical, Inc.
Sep 09, 2026, 07:05 ET Aurora Appoints Seasoned Biopharmaceutical Executive to Lead Commercial Acceleration of Global Medical Cannabis Business
spanning innovative medicines, oncology, specialty care, vaccines and consumer healthcare. He has held progressive leadership roles at JAMP Pharma Group, GSK and AstraZeneca, building deep commercial expertise across global markets including Canada, the U.S., Europe and Asia. Throughout his career, Faris has
More news about: Aurora Cannabis Inc.
Sep 08, 2026, 10:31 ET Sarcoidosis Market Forecast: Emerging Therapies and Increasing Disease Awareness to Drive Expansion by 2036 | DelveInsight
the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key ILD companies including GSK, Insmed, Gossamer Bio, Chiesi Farmaceutici, Liquidia Corporation, Bristol-Myers Squibb, Emphycorp, aTyr Pharma, PureTech Health, Endeavor Biomedicines,
More news about: DelveInsight Business Research, LLP
Sep 03, 2026, 10:31 ET Osteosarcoma Market is Set to Rise by 2036 as 8 Emerging Therapies Set to Drive Future Growth | DelveInsight
with emerging therapies such as OST-HER2 (OS Therapies), DANYELZA (naxitamab-gqgk; SERB Pharmaceutical), Vactosertib (MedPacto), Risvutatug rezetecan (GSK), Olaparib with Ceralaserti (AstraZeneca), OMO-103 (Peptomyc), Eflornithine (DFMO) and AMXT 1501 (Aminex Therapeutics), PEEL-224 (Peel Therapeutics),
More news about: DelveInsight Business Research, LLP
Sep 02, 2026, 08:30 ET Halozyme to Participate at Upcoming Investor Conferences
Janssen, AbbVie, Eli Lilly, Bristol-Myers Squibb, argenx, ViiV Healthcare, Chugai Pharmaceutical, Acumen Pharmaceuticals, Merus N.V., Skye Bioscience, GSK and Incyte.Halozyme expanded its drug delivery technology portfolio to develop partner products using Hypercon™ and Surf Bio's hyperconcentration
More news about: Halozyme Therapeutics, Inc.
Aug 27, 2026, 22:44 ET Akeso 2026 Interim Results: Strong Commercialization Momentum; IO2.0+ Global Strategy Redefining Clinical Standards; Bispecific Advancement in ADC, I&I and Alzheimer's
parallel, ivonescimab has entered combination therapy collaborations with high-potential ADCs from domestic and international partners, including Pfizer, GSK, Biokin, and MediLink. These collaborations cover agents such as EGFR/HER3 bispecific ADC, TROP2/HER3 bispecific ADC, B7H3 ADC, FGFR2b ADC, TROP2 ADC,
More news about: Akeso, Inc.
Aug 26, 2026, 10:41 ET Oncolytic Virus Cancer Therapy Market Expected to Expand Rapidly During the Forecast Period (2026-2036) Amid Rising Investments in Next-Generation Cancer Treatments| DelveInsight
Lilly and Company, Merck, Regeneron, Sanofi, Ono Pharmaceutical, Novartis, Genentech, Roche, Amgen, Chugai Laboratories, Moderna Therapeutics, Pfizer, GSK and others.
More news about: DelveInsight Business Research, LLP
Aug 26, 2026, 07:00 ET Vivace Therapeutics Strengthens Leadership Team as It Prepares to Advance VT3989, the First TEAD Inhibitor to enter Phase 3 Clinical Trials, as the Leading Treatment for Mesothelioma
tumor (GIST). Under his leadership, IDRx advanced through key development, financial, and strategic inflection points, culminating in its acquisition by GSK for up to $1.15 billion. Earlier, he served as Chief Executive Officer of Theseus Pharmaceuticals, President of Xilio Therapeutics, and as President
More news about: Vivace Therapeutics, Inc.
Aug 24, 2026, 10:31 ET Liver Cirrhosis Market to Expand Significantly Through 2036, Driven by Emerging Therapies and Increasing Disease Burden | DelveInsight
historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key ALD companies, including Bausch Health, GSK, Alfasigma (Intercept Pharmaceuticals), Altimmune, Nterica, and others.
More news about: DelveInsight Business Research, LLP
Aug 20, 2026, 10:02 ET ISASecure to Develop Certification Scheme for Commercial Components Procured by US Government
and supplier development practices since 2010.Founders and key supporters of ISASecure include BP, Chevron, ExxonMobil, Saudi Aramco, Shell, GSK, Honeywell, Johnson Controls, Schneider Electric, Yokogawa, Carrier, Siemens, YPF, Amazon Web Services, exida, TUV Rheinland, CSSC, FM Approvals, Synopsys,
More news about: The International Society of Automation
Aug 20, 2026, 06:45 ET Cumulus Neuroscience annonce la publication d'un article dans Scientific Reports démontrant que la plateforme NeuLogiq® est viable et utilisable pour l'évaluation cognitive multimodale à domicile chez les personnes atteintes de sclérose latérale amyotrophique (SLA) et de dégénérescence fronto-temporale (DFT)
consortium préconcurrentiel regroupant plusieurs laboratoires pharmaceutiques, notamment Biogen, Boehringer Ingelheim, Bristol Myers Squibb, Eli Lilly, GSK et Takeda. Un article complémentaire présentera les résultats de l'EEG obtenus auprès de cette même cohorte.La SLA est une maladie neurodégénérative
More news about: Cumulus Neuroscience
Aug 20, 2026, 02:14 ET Cumulus Neuroscience gibt die Veröffentlichung eines Artikels in der Fachzeitschrift „Scientific Reports" bekannt, der belegt, dass die NeuLogiq®-Plattform für die multimodale kognitive Beurteilung von Menschen mit ALS und FTD zu Hause geeignet und einsetzbar ist
Zusammenarbeit mit einem vorwettbewerblichen Konsortium von Pharmaunternehmen entwickelt, zu dem Biogen, Boehringer Ingelheim, Bristol Myers Squibb, Eli Lilly, GSK und Takeda gehörten. In einer Folgeveröffentlichung werden die EEG-Befunde derselben Kohorte vorgestellt.ALS ist eine fortschreitende neurodegenerative
More news about: Cumulus Neuroscience
Aug 19, 2026, 07:46 ET Hengrui Pharma Reports 2026 Interim Results as Innovation and Globalization Continue to Drive Business Momentum
total potential transaction value of approximately US$42 billion. These collaborations include leading global pharmaceutical companies such as BMS, GSK and others.Among the diversified collaboration models Hengrui has explored, NewCo has also seen important progress in 2026. Kailera Therapeutics
More news about: Hengrui Pharma
Aug 18, 2026, 16:01 ET Halozyme Appoints Dannielle Appelhans to its Board of Directors
Janssen, AbbVie, Eli Lilly, Bristol-Myers Squibb, argenx, ViiV Healthcare, Chugai Pharmaceutical, Acumen Pharmaceuticals, Merus N.V., Skye Bioscience, GSK and Incyte.Halozyme expanded its drug delivery technology portfolio to develop partner products using Hypercon™ and Surf Bio's hyperconcentration
More news about: Halozyme Therapeutics, Inc.
Aug 18, 2026, 12:06 ET Cumulus Neuroscience Announces Publication in Scientific Reports Demonstrating the NeuLogiq® Platform Is Feasible and Usable for At-Home, Multimodal Cognitive Assessment in People Living with ALS and FTD
collaboration with a pre-competitive consortium of pharmaceutical companies, including Biogen, Boehringer Ingelheim, Bristol Myers Squibb, Eli Lilly, GSK and Takeda. A follow-up paper will report the EEG findings from the same cohort.ALS is a progressive neurodegenerative disease that affects nerve
More news about: Cumulus Neuroscience
Aug 18, 2026, 11:44 ET Cumulus Neuroscience Announces Publication in Scientific Reports Demonstrating the NeuLogiq® Platform Is Feasible and Usable for At-Home, Multimodal Cognitive Assessment in People Living with ALS and FTD
collaboration with a pre-competitive consortium of pharmaceutical companies, including Biogen, Boehringer Ingelheim, Bristol Myers Squibb, Eli Lilly, GSK and Takeda. A follow-up paper will report the EEG findings from the same cohort.ALS is a progressive neurodegenerative disease that affects nerve
More news about: Cumulus Neuroscience
Aug 18, 2026, 09:00 ET PM360 Announces 2026 Trailblazer Award Finalists
Bechily, Head of Marketing, PharmaEssentiaInfectious Disease/Vaccine Development: Rob Peck, Marketing Director, Customer Experience, GSK VaccinesInnovation/Digital Strategy: Steven Xie, Vice President, Enterprise Omnichannel & Communications, ApnimedManaged
More news about: PM360
Aug 18, 2026, 03:04 ET WuXi Biologics Recognized for Industry Top Sustainable Biopharma Practices Empowering the Industry's Transformation Through Green CRDMO
operations. The list brings together global pharmaceutical leaders – such as MSD (Merck & Co.), Eli Lilly, Johnson & Johnson, AstraZeneca, Takeda, GSK and Bayer – collectively illustrating the diverse pathways through which players across the industry value chain are advancing the green transition,
More news about: WuXi Biologics
Aug 13, 2026, 10:31 ET Bronchiectasis Market is Expected to Surge at a CAGR of 15% by 2036, Owing to the Launch of DPP1/CatC Inhibitors, Therapeutic Phage Cocktails, Nebulized Mucoactive Agents, and Other Novel Mechanisms | DelveInsight
promising bronchiectasis therapies in clinical trials include Verducatib (BI 1291583), AP-PA02, ARINA-1 (RVN-301), HSK31858, CHF 6333, CSL787, GSK3862995, and others.Discover Insmed BRINSUPRI FDA approval status bronchiectasis 2025 @
More news about: DelveInsight Business Research, LLP
Aug 12, 2026, 08:09 ET Iterion Therapeutics Strengthens Board with Additions of Manuel Aivado, MD, PhD and Bob Smith
distinguished track record in clinical development leading multiple investigational assets from early clinical stage to approval during his tenure at Taiho and GSK. Dr. Aivado brings substantial expertise in oncology drug development and company building, providing valuable strategic guidance to support Iterion's
More news about: Iterion Therapeutics
Aug 11, 2026, 22:14 ET 건강한 노화 혁신 위한 1억 100만 달러 규모 엑스프라이즈 헬스스팬 대회에서 결선 진출 10개 팀에 각각 100만 달러 수여
solvefshd.com을 방문하면 솔브 FSHD의 활동에 대해 자세히 알아볼 수 있다.GSK 소개GSK는 질병보다 앞서 나가기 위해 과학, 기술 및 인재를 하나로 모으는 것을 목표로 하는 글로벌 바이오제약 기업이다. 자세한 내용은
More news about: XPRIZE
Aug 11, 2026, 09:00 ET 10 Finalist Teams Awarded $1M to Advance in XPRIZE Healthspan $101 Million Race to Transform Healthy Aging
solvefshd.comAbout GSKGSK is a global biopharma company with a purpose to unite science, technology, and talent to get ahead of disease together. Find out more at
More news about: XPRIZE
Aug 10, 2026, 08:30 ET Theravance Biopharma, Inc. Reports Second Quarter 2026 Financial Results and Provides Corporate Update
reduction in operating expenses year-over-year (excluding restructuring and transaction costs)Q2 2026 TRELEGY net sales, reported by GSK, of approximately $1.0 billion; high confidence in achieving the $100 million 2026 milestone payment2Quarter-end cash
More news about: Theravance Biopharma, Inc.
Aug 06, 2026, 16:01 ET HALOZYME REPORTS RECORD SECOND QUARTER 2026 RESULTS, BEATS ESTIMATES AND RAISES FULL YEAR 2026 FINANCIAL GUIDANCE
seronegative.In May 2026, Halozyme and GSK plc ("GSK") entered into a global collaboration and license agreement for ENHANZE® with multiple oncology targets, including the first potential application in antibody-drug conjugates. Under the terms of the agreement, GSK made an upfront payment and agreed
More news about: Halozyme Therapeutics, Inc.
Aug 06, 2026, 10:31 ET The Next Billion-Dollar Opportunity in Alzheimer's Disease Market: 6 Pipeline Therapies to Watch | DelveInsight
including ARS Pharmaceuticals, Alfresa Pharma, Roche, Stallergenes Greer, DBV Technologies, Aquestive Therapeutics, Aravax, Siolta Therapeutics, GSK, Cue Biopharma, N-Fold, InnoUp Farma, Allergy Therapeutics, UKKO, Bryn Pharma, Poplar Therapeutics, Inimmune, Novartis (Excellergy), Intrommune Therapeutics,
More news about: DelveInsight Business Research, LLP